BRPI0414311A - formas de dosagem de liberação controlada - Google Patents
formas de dosagem de liberação controladaInfo
- Publication number
- BRPI0414311A BRPI0414311A BRPI0414311-6A BRPI0414311A BRPI0414311A BR PI0414311 A BRPI0414311 A BR PI0414311A BR PI0414311 A BRPI0414311 A BR PI0414311A BR PI0414311 A BRPI0414311 A BR PI0414311A
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- present
- formula
- release
- provides
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 16
- 229940079593 drug Drugs 0.000 abstract 16
- 210000001072 colon Anatomy 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000000541 pulsatile effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
FORMAS DE DOSAGEM DE LIBERAçãO CONTROLADA. A presente invenção se relaciona a uma forma de dosagem para administração oral que preferencialmente libera a droga no o cólon. A presente invenção é adicionalmentemente relacionada a métodos de preparar tais formulações, e métodos de tratamento utilizando tais formulações. é um objeto da presente invenção prover uma fórmula de dosagem farmacêutica oral que formar que preveja o atraso da liberação da(s) droga(s) no cólon de um ser humano depois de ingestão oral da fórmula dosada. é um objeto adicionalmentemente de certas incorporações da presente invenção prover uma fórmula de dosagem farmacêutica oral que provê um atraso para liberar demora liberar uma(s) droga(s) na área gastrintestinal de um ser humano como isso a droga é liberada no cólon. é um objeto adicionalmentemente de certas incorporações da presente invenção para prover uma fórmula de dosagem farmacêutica tendo um núcleo contendo droga, o núcleo sendo comprimido e coberto com uma coberta com uma camada que provê um atraso para liberar a fórmula de dosagem depois da dosagem ser oralmente administrada para um ser humano. é um objeto adicionalmentemente de certas incorporações da presente invenção para prover uma fórmula de dosagem farmacêutica oral tendo uma droga contenda um núcleo que é comprimida e coberta com uma camada que provê um atraso para liberar a droga quando a fórmula de dosagem for oralmente administrado em um ser humano. é um objeto adicionalmentemente de certas incorporações da presente invenção para prover uma fórmula que permite a dosagem para especificamente o cólon atuando para uma larga variedade de doenças. é um objeto adicionalmentemente de certas Incorporações da presente invenção para prover dosagem forma atuando em doenças como colite ulcerativa, Doença do Crohn ou outras doenças que são tipicamente mais sintomáticas em área gastrintestinal inferior. é um objeto adicionalmentemente de certas incorporações da presente invenção para prover uma fórmula de dosagem que prevê um atraso para liberar a droga da fórmula de dosagem tal que a droga é liberada no cólon, seguido por um liberação controlada da droga depois disso. é um objeto adicionalmentemente de certas incorporações da presente invenção prover uma compressão da cobertura da fórmula de dosagem tendo uma imediata liberação da camada de uma(s) droga(s) com uma sobre cobertura sobre o núcleo comprimido que prevê um atraso para liberar a mesma droga ou diferente(s) da fórmula de dosagem; o núcleo opcionalmente provendo um liberação controlada da droga depois disso. é um objeto adicionalmentemente de certas incorporações da presente invenção prover uma fórmula de dosagem oral que provê um local de liberação específico de droga (P,.ex., para o cólon). é um objeto adicionalmentemente de certas incorporações da presente invenção para desenvolver uma fórmula de dosagem oral que prevê liberação programada da droga. é um objeto adicionalmentemente de certas incorporações da presente invenção para desenvolver uma fórmula de dosagem oral que prevê a liberação pulsativa da droga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50403503P | 2003-09-19 | 2003-09-19 | |
| PCT/US2004/030450 WO2005027878A1 (en) | 2003-09-19 | 2004-09-17 | Delayed released dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414311A true BRPI0414311A (pt) | 2008-03-04 |
Family
ID=34375438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414311-6A BRPI0414311A (pt) | 2003-09-19 | 2004-09-17 | formas de dosagem de liberação controlada |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8389008B2 (pt) |
| EP (1) | EP1670442A4 (pt) |
| JP (1) | JP2007505921A (pt) |
| KR (1) | KR100782918B1 (pt) |
| CN (1) | CN1882316A (pt) |
| AP (1) | AP2006003585A0 (pt) |
| BR (1) | BRPI0414311A (pt) |
| CA (1) | CA2539051C (pt) |
| EA (1) | EA200600598A1 (pt) |
| IL (1) | IL174343A0 (pt) |
| MX (1) | MXPA06003100A (pt) |
| NZ (1) | NZ545921A (pt) |
| WO (1) | WO2005027878A1 (pt) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1067910T3 (da) | 1998-04-03 | 2004-10-04 | Egalet As | Komposition med styret afgivelse |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| WO2004041252A1 (en) | 2002-11-08 | 2004-05-21 | Egalet A/S | Controlled release carvedilol compositions |
| DE602004014747D1 (de) | 2003-03-26 | 2008-08-14 | Egalet As | Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| CA2592605C (en) * | 2004-12-27 | 2010-12-07 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| NZ563846A (en) * | 2005-06-03 | 2010-03-26 | Egalet As | A drug delivery system for delivering active substances dispersed in a dispersion medium |
| GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| EP2081555A2 (en) * | 2006-09-12 | 2009-07-29 | Cosmo Technologies Ltd. | Pharmaceutical compositions for the oral or rectal administration of protein substances |
| US20080152709A1 (en) * | 2006-12-22 | 2008-06-26 | Drugtech Corporation | Clonidine composition and method of use |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| CN101134785B (zh) * | 2007-08-17 | 2010-08-18 | 浙江大学 | 结肠菌群降解材料及其制备方法和用途 |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| EP2163240A1 (en) * | 2008-09-12 | 2010-03-17 | Universita' Degli Studi Di Genova | A method for the production of bioadhesive compact matrices |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| US8945615B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
| US8945616B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| JP5885668B2 (ja) | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ， インコーポレイテッド | アマンタジン組成物および使用方法 |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2012094636A2 (en) | 2011-01-07 | 2012-07-12 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| JP6025755B2 (ja) | 2011-02-11 | 2016-11-16 | ズィーエックス ファーマ，エルエルシー | 多粒子ｌ−メントール製剤及びその関連する方法 |
| US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| BR112014016808B1 (pt) | 2012-01-06 | 2022-01-11 | Anji Pharma (Us) Llc | Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose |
| CN104349773A (zh) | 2012-01-06 | 2015-02-11 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| PE20151301A1 (es) | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| BR112015006499A2 (pt) | 2013-04-23 | 2017-07-04 | Zx Pharma Llc | composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| CA2926691A1 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
| JP7211704B2 (ja) * | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| EP3402804A1 (en) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations and methods for treating ulcerative colitis |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| CN106420649A (zh) * | 2016-11-21 | 2017-02-22 | 中国药科大学 | 一种基于聚电解质自组装膜的对乙酰氨基酚压制包衣控释片及其制备方法 |
| AU2018212273B2 (en) | 2017-01-26 | 2023-12-21 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| CN107348514A (zh) * | 2017-06-29 | 2017-11-17 | 安徽康博特保健食品有限公司 | 一种低糖型铁叶酸片的制备方法 |
| CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
| CN111698983B (zh) | 2018-01-09 | 2022-10-18 | 南京三迭纪医药科技有限公司 | 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型 |
| CN113018273B (zh) * | 2019-12-25 | 2024-08-09 | 上海宣泰医药科技股份有限公司 | 一种固体制剂及其制备方法和用途 |
| US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
| US20240041779A1 (en) * | 2020-12-08 | 2024-02-08 | Triastek, Inc. | Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of use |
| KR20260020183A (ko) | 2023-06-05 | 2026-02-10 | 나노파마슈틱스, 인크. | 서방성 결정질 prx-3140의 경구 전달을 위한 조성물 및 방법 |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131123A (en) | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
| US4248858A (en) | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4851231A (en) | 1982-12-13 | 1989-07-25 | Alza Corporation | System for delivering drug in selected environment of use |
| US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| SE457505B (sv) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| DK62184D0 (da) | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| US4853249A (en) | 1985-11-15 | 1989-08-01 | Taisho Pharmaceutical Co., Ltd. | Method of preparing sustained-release pharmaceutical/preparation |
| IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
| JPS62195323A (ja) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
| US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| IT1204294B (it) | 1986-03-11 | 1989-03-01 | Gentili Ist Spa | Metodo di fabbricazione di granulari atti a produzione di compresse rivestite,per uso orale,a rilascio controllato |
| US5238686A (en) | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US4842867A (en) | 1986-05-09 | 1989-06-27 | Alza Corporation | Pulsed drug delivery of doxylamine |
| IE58401B1 (en) | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
| GB8628359D0 (en) | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| SE460945B (sv) | 1987-01-15 | 1989-12-11 | Lejus Medical Ab | En multipel-unit-dos komposition av furosemid |
| GB8702411D0 (en) | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
| GB8717168D0 (en) | 1987-07-21 | 1987-08-26 | Roussel Lab Ltd | Controlled-release device |
| NO883326L (no) | 1987-08-11 | 1989-02-13 | Bayer Ag | Dhp-retard-tilberedning. |
| US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| US4841231A (en) | 1987-10-30 | 1989-06-20 | Unisys Corporation | Test probe accessibility method and tool |
| US4971805A (en) | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
| JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| US4857337A (en) | 1988-05-24 | 1989-08-15 | American Home Products Corp. (Del) | Enteric coated aspirin tablets |
| US5468746A (en) | 1988-07-29 | 1995-11-21 | Zambon Group S.P.A. | Compounds active on the cardiovascular system |
| US5047246A (en) | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| US5128143A (en) | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
| US5169639A (en) | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US5334372A (en) | 1988-10-07 | 1994-08-02 | Kao Corporation | Alcohol-modified silicon ester derivative and cosmetic composition containing same |
| IT1230576B (it) | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
| IT1227899B (it) | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5032406A (en) | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| PH27186A (en) | 1989-09-07 | 1993-04-16 | Ciba Geigy Ag | Double-coated granules of disodium pamidronate |
| GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
| EP0441119A3 (en) | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5198227A (en) | 1990-01-22 | 1993-03-30 | Mcneil-Ppc, Inc. | Dual subcoated simulated capsule medicament |
| US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| US5158777A (en) | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| US5175003A (en) | 1990-04-06 | 1992-12-29 | Biosytes Usa, Inc. | Dual mechanism controlled release system for drug dosage forms |
| US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| IE61651B1 (en) | 1990-07-04 | 1994-11-16 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5202338A (en) | 1990-10-31 | 1993-04-13 | Vilmos Bar | Dihydroquinoline derivatives, pharmaceutical compositions and methods of use of dihydroquinoline derivatives as modulators of the arachidonic acid cascade |
| US5316772A (en) | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| US5232706A (en) | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
| US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
| US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
| IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
| US5234947A (en) | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| IT1260505B (it) | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
| US5262172A (en) | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
| US5302400A (en) | 1992-06-22 | 1994-04-12 | Digestive Care Inc. | Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids |
| NL9201195A (nl) | 1992-07-03 | 1994-02-01 | Tno | Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat. |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| JPH072650A (ja) | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
| EP0711166A1 (en) | 1993-07-22 | 1996-05-15 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399358A (en) | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
| US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
| US5407687A (en) | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| US5374759A (en) | 1994-03-22 | 1994-12-20 | Siltech Inc. | Silicone esters of hydroxy acid |
| US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| US5536507A (en) | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
| GB9416600D0 (en) | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US6103263A (en) | 1994-11-17 | 2000-08-15 | Andrx Pharmaceuticals, Inc. | Delayed pulse release hydrogel matrix tablet |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| US5656294A (en) * | 1995-06-07 | 1997-08-12 | Cibus Pharmaceutical, Inc. | Colonic delivery of drugs |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US5713852A (en) | 1995-06-07 | 1998-02-03 | Alza Corporation | Oral dosage and method for treating painful conditions of the oral cavity |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| AU2068797A (en) | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
| US6156340A (en) | 1996-03-29 | 2000-12-05 | Duquesne University Of The Holy Ghost | Orally administrable time release drug containing products |
| JP3148256B2 (ja) | 1996-07-08 | 2001-03-19 | エドワード メンデル カンパニー．，インコーポレーテッド | 高用量難溶性薬物用持続放出マトリックス |
| US5792476A (en) | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5788987A (en) | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| US5922352A (en) | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US5958873A (en) | 1997-06-09 | 1999-09-28 | University Of Cincinnati | Oral formulation for treatment of bacteria-induced diseases of the colon |
| KR100219918B1 (ko) | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
| IN186245B (pt) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| KR20040047747A (ko) * | 2001-03-13 | 2004-06-05 | 펜웨스트 파머슈티칼즈 컴파니 | 변시치료 제형 |
| BR0307593A (pt) * | 2002-02-07 | 2005-02-01 | Pharmacia Corp | Comprimidos farmacêuticos |
-
2004
- 2004-09-17 EA EA200600598A patent/EA200600598A1/ru unknown
- 2004-09-17 US US10/943,356 patent/US8389008B2/en not_active Expired - Lifetime
- 2004-09-17 AP AP2006003585A patent/AP2006003585A0/xx unknown
- 2004-09-17 BR BRPI0414311-6A patent/BRPI0414311A/pt not_active Application Discontinuation
- 2004-09-17 CA CA2539051A patent/CA2539051C/en not_active Expired - Fee Related
- 2004-09-17 MX MXPA06003100A patent/MXPA06003100A/es active IP Right Grant
- 2004-09-17 EP EP04784340A patent/EP1670442A4/en not_active Withdrawn
- 2004-09-17 NZ NZ545921A patent/NZ545921A/en unknown
- 2004-09-17 KR KR1020067005515A patent/KR100782918B1/ko not_active Expired - Fee Related
- 2004-09-17 CN CNA2004800342677A patent/CN1882316A/zh active Pending
- 2004-09-17 WO PCT/US2004/030450 patent/WO2005027878A1/en not_active Ceased
- 2004-09-17 JP JP2006527046A patent/JP2007505921A/ja active Pending
-
2006
- 2006-03-16 IL IL174343A patent/IL174343A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8389008B2 (en) | 2013-03-05 |
| MXPA06003100A (es) | 2006-06-20 |
| CN1882316A (zh) | 2006-12-20 |
| KR100782918B1 (ko) | 2007-12-07 |
| IL174343A0 (en) | 2009-02-11 |
| AP2006003585A0 (en) | 2006-04-30 |
| CA2539051C (en) | 2014-08-12 |
| EP1670442A1 (en) | 2006-06-21 |
| AU2004273956A1 (en) | 2005-03-31 |
| EA200600598A1 (ru) | 2006-08-25 |
| KR20060070565A (ko) | 2006-06-23 |
| CA2539051A1 (en) | 2005-03-31 |
| WO2005027878A1 (en) | 2005-03-31 |
| JP2007505921A (ja) | 2007-03-15 |
| EP1670442A4 (en) | 2011-09-14 |
| NZ545921A (en) | 2009-09-25 |
| US20050112201A1 (en) | 2005-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| BRPI0213175B8 (pt) | forma galênica oral macroparticulada para a liberação retardada e controlada de um princípios ativos farmacêuticos e uso de microcápsulas "reservatório" | |
| HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2009525985A5 (pt) | ||
| JP2013231087A5 (pt) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| WO2007103200A3 (en) | Oral controlled release formulation for sedative and hypnotic agents | |
| JP2010522242A5 (pt) | ||
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| RU2010105122A (ru) | Композиции для ухода за полостью рта, продукты и способы применения | |
| BR112013006597A2 (pt) | tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| JP2016540021A5 (pt) | ||
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| ECSP15042897A (es) | Formulaciones orales de deferasirox | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| JP2008543936A5 (pt) | ||
| CO5060477A1 (es) | Forma de dosificacion de nefazodona | |
| JP2014001235A5 (pt) | ||
| JP2018527305A5 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |